<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The majority of patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> become anemic during the course of their disease </plain></SENT>
<SENT sid="1" pm="."><plain>This <z:hpo ids='HP_0001903'>anemia</z:hpo> appears to be due largely to a blunted erythropoietin (Epo) response and an impaired ability of the bone marrow to respond to endogenous Epo </plain></SENT>
<SENT sid="2" pm="."><plain>Both are exacerbated by chemotherapy and radiation therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Recombinant human erythropoietin (rhEpo) ameliorates the <z:hpo ids='HP_0001903'>anemia</z:hpo> associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>However, we do not yet know whether rhEpo will decrease the need for homologous blood transfusions and improve the quality of life of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>While rhEpo will greatly alter the treatment of <z:hpo ids='HP_0001903'>anemia</z:hpo> in the 1990s, its precise role in the treatment of <z:hpo ids='HP_0002664'>oncology</z:hpo> patients is still being elucidated </plain></SENT>
</text></document>